3 results match your criteria: "Inner Mongolia Research Center for Drug Screening[Affiliation]"
BMC Pharmacol Toxicol
April 2022
Inner Mongolia Research Center for Drug Screening, Hohhot, China.
Background: The main causes of lung cancer are smoking, environmental pollution and genetic susceptibility. It is an indisputable fact that PAHs are related to lung cancer, and benzo(a) pyrene is a representative of PAHs. The purpose of the current investigation was to investigate the interaction between AhR and HIF-1 signaling pathways in A549 cells, which provide some experimental basis for scientists to find drugs that block AhR and HIF-1 signaling pathway to prevent and treat cancer.
View Article and Find Full Text PDFLipids Health Dis
January 2022
Department of Pharmacology of Pharmaceutical College, Inner Mongolia Medical University, Hohhot, 010010, China.
Background: Benzo [a] pyrene (BaP), a potent carcinogen, has been proved that it has toxicological effects via activation the aryl hydrocarbon receptor (AhR) pathway. AhR can participate in regulating lipogenesis and lipolysis. This topic will verify whether BaP regulates lipid metabolism via AhR.
View Article and Find Full Text PDFCurr Med Sci
June 2020
Department of Pharmacology of Pharmaceutical College, Inner Mongolia Medical University, Hohhot, 010010, China.
In order to demonstrate the relationship between methylation of fragile histidine triad (FHIT) and T-cadherin/H-cadherin (CDH13) genes and liver cancer, the methylation status of FHIT and CDH13 was detected in healthy individuals and in Mongolian and Han patients with liver cancer. The phenol-chloroform method was used to extract genomic DNA. The methylation specific polymerase chain reaction method was applied to detect the methylation status of FHIT and CDH13.
View Article and Find Full Text PDF